Arcellx's Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) demonstrated a 97% overall response rate and 68% complete response rate in 117 patients with relapsed/refractory multiple myeloma.
Anitocabtagene autoleucel (anito-cel) utilizes a novel D-Domain binder for BCMA targeting, offering potentially higher transduction efficiency and CAR density compared to traditional CAR T therapies.
Researchers from Sylvester Comprehensive Cancer Center will deliver 9 oral presentations, 4 rapid oral presentations, and 51 poster presentations at the upcoming ASCO 2025 Annual Meeting, showcasing significant advances across multiple cancer types.
Gilead Sciences and Merck's phase 3 ASCENT-04/KEYNOTE-D19 trial demonstrated statistically significant improvement in progression-free survival with Trodelvy plus Keytruda compared to Keytruda with chemotherapy in metastatic TNBC patients.
DARZALEX (daratumumab), Janssen's CD38-targeting monoclonal antibody, has transformed multiple myeloma treatment across all lines of therapy, generating $11.6 billion in worldwide sales in 2024.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.